Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 9/20 | 0.55 |
| ▸ | ITGB2 | P05107 | 8/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 8/20 | 0.55 |
| ▸ | CCNC | P24863 | 4/20 | 0.44 |
| ▸ | CDK8 | P49336 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196589 | 0.91 | ITGB2 (0.53) | ITGALITGB2ICAM1CCNCCDK8 | |
| SCHEMBL6197437 | 0.91 | ITGAL (0.66) | ITGALITGB2ICAM1CCNCCDK8 | |
| SCHEMBL6199405 | 0.88 | ITGB2 (0.53) | ITGALITGB2ICAM1CCNCCDK8 | |
| SCHEMBL6198445 | 0.87 | ITGB2 (0.53) | ITGALITGB2ICAM1CCNCCDK8 | |
| SCHEMBL6202870 | 0.83 | ITGB2 (0.48) | ITGALITGB2ICAM1CCNCCDK8 | |
| SCHEMBL6198429 | 0.83 | ITGB2 (0.54) | ITGALITGB2ICAM1CCNCCDK8 | |
| SCHEMBL6199336 | 0.83 | HTT (0.51) | ITGALITGB2ICAM1CCNCCDK8 | |
| SCHEMBL6310320 | 0.83 | ITGB2 (0.51) | ITGALITGB2ICAM1CCNCCDK8 | |
| SCHEMBL6197411 | 0.80 | ITGAL (0.83) | ITGALITGB2ICAM1NPC1RAB9A | |
| SCHEMBL6219767 | 0.78 | NPC1 (0.47) | ITGALITGB2ICAM1CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | disclosed |
| EP-1140814-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6867203-B2 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1481968-A2 | Cell adhesion-inhibiting anti-inflammatory and immune-suppressive compounds | Abbott Laboratories (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1165505-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ICAM1, VCAM1, EPCAM | ITGAL 57/4885ITGB2 32/4885ICAM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.